NATICK, Mass., July 13 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced CE Mark for its LATITUDE® Patient Management system. The LATITUDE system remotely monitors patients with implantable cardiac devices, gathering information on both the device and a patient's heart health status. The system can also detect clinical events between scheduled physician visits and send relevant data directly to a patient's physician. It will be launched in Europe in a phased approach beginning this week.

"The wireless LATITUDE system will enable me to more closely monitor my patients while helping manage hospital workflow," said Konstantin M. Heinroth, M.D., Department of Medicine, Martin Luther University Halle-Wittenberg, Halle, Germany. "I hope to provide my patients added convenience and the peace of mind that comes from knowing both their device and heart health status can be monitored."

"Boston Scientific has enrolled more than 130,000 patients on the LATITUDE system since its introduction in the U.S. in 2006, making it the most rapidly adopted remote cardiac device monitoring system in the industry(1)," said Fred Colen, President, Boston Scientific Cardiac Rhythm Management. "We expect continued success as we introduce the demonstrated benefits of our LATITUDE system to patients and physicians in Europe. Remote monitoring technology provides a significant opportunity to further improve patient care."

The LATITUDE system provides physicians actionable information that enables them to see changes in their patients' cardiac health sooner than regularly scheduled follow-up visits. LATITUDE is the only remote cardiac device monitoring system to offer a wireless weight scale and blood pressure monitor, both of which are recommended by the European Society of Cardiology for the management of Class I heart failure patients.

The international version of the LATITUDE system is compatible with the Company's wireless TELIGEN® implantable cardioverter defibrillator (ICD) and COGNIS® cardiac resynchronization therapy defibrillator (CRT-D), the world's smallest and thinnest high-energy devices.

The first enrollments of European patients onto the LATITUDE system were performed by J.H. Ruiter, M.D., Medisch Centrum Alkmaar, Alkmaar, The Netherlands, and Peter Mortensen, M.D., Chief Physician, SkejbyUniversityHospital, Aarhus, Denmark.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, scientific activities, product performance, competitive offerings and growth investment. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

(1) Data based on number of patients at three years post-launch. Data on file.

    CONTACT:        David Knutson
                    651-582-6574 (office)
                    651-260-8288 (mobile)
                    Media Relations
                    Boston Scientific Corporation

                    Larry Neumann
                    508-650-8696 (office)
                    Investor Relations
                    Boston Scientific Corporation

SOURCE Boston Scientific Corporation

SOURCE: Boston Scientific Corporation

Web site: http://www.bostonscientific.com/